Which adverse effect unique to vancomycin is caused by histamine release?

A. Keep the serum drug level within the therapeutic margin:

This is the correct goal of monitoring peak and trough levels during antibacterial therapy. The therapeutic margin refers to the range of drug concentrations in the bloodstream that achieves optimal therapeutic effects while avoiding toxicity. By monitoring peak and trough levels, healthcare providers can adjust the dosing regimen to maintain drug levels within this therapeutic margin.

B. Increase the therapeutic effect of the drug by gradually decreasing the drug dose:

This statement is incorrect. Monitoring peak and trough levels is not about increasing the therapeutic effect of the drug by gradually decreasing the drug dose. Instead, it's about ensuring that the drug levels are maintained within the appropriate therapeutic range to achieve optimal efficacy without causing adverse effects.

C. Provide maximum physical comfort to the patient:

Monitoring peak and trough levels is not primarily aimed at providing physical comfort to the patient. While optimizing drug therapy can contribute to improved clinical outcomes and patient well-being, the goal of monitoring these levels is specifically related to achieving therapeutic drug concentrations.

D. Treat the main disorder with no psychological distress to the patient:

This statement is unrelated to the goal of monitoring peak and trough levels during antibacterial therapy. While psychological distress may be a consideration in patient care, the primary goal of monitoring drug levels is to ensure therapeutic efficacy and safety.

A. The herbal product must contain only one active ingredient:

This statement is not a legal requirement contained in DSHEA. Many dietary supplements contain multiple active ingredients, such as vitamins, minerals, herbs, amino acids, and other substances. DSHEA does not mandate that dietary supplements contain only one active ingredient.

B. Effectiveness must be demonstrated by the manufacturer:

DSHEA does not require manufacturers to demonstrate the effectiveness of dietary supplements before marketing. Unlike pharmaceutical drugs, which must undergo premarket approval by the Food and Drug Administration (FDA) to demonstrate safety and efficacy, dietary supplements do not need to prove effectiveness to be marketed. Instead, manufacturers are responsible for ensuring the safety of their products and making truthful claims on product labels.

C. Dietary supplements must state that the product is not intended to diagnose, treat, cure, or prevent any disease:

This statement accurately reflects a legal requirement contained in DSHEA. Under DSHEA, dietary supplement labels must include a disclaimer stating that the product is not intended to diagnose, treat, cure, or prevent any disease. This disclaimer helps to clarify that dietary supplements are intended to support general health and well-being rather than to treat specific diseases or medical conditions.

D. Dietary supplements must be tested for safety prior to marketing:

While DSHEA requires manufacturers to ensure the safety of their dietary supplements, it does not mandate standardized premarket testing for safety by regulatory authorities. Instead, manufacturers are responsible for conducting safety assessments and ensuring that their products are safe for consumers. The FDA may take action against manufacturers if a product is found to be unsafe or if it violates regulatory requirements, but premarket testing is not a specific legal requirement under DSHEA.